Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 Pharmacokinetics and Safety in Healthy Male Subjects
NCT07560033Phase 1Not yet recruiting
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial of CM326 (2 arms), sponsored by CSPC Baike Biopharmaceutical. Primary endpoints: Maximum concentration and Area under the concentration-time curve from zero to infinity. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
CM326
Beyond the preview
Go deeper on NCT07560033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560033.